Glaxo, Shionogi Say HIV Drug Beats Gilead Atripla in Test

An experimental treatment for HIV developed by GlaxoSmithKline Plc, Pfizer Inc. and Shionogi & Co. reduced the virus in more people than Gilead Sciences Inc.’s Atripla, suggesting it may supplant the world’s best-selling AIDS medicine as the preferred front-line therapy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.